Could Beta blockade improve outcome after injury by modulating inflammatory profiles?

Area of Science:

• Cardiology
• Critical Care Medicine
• Immunology

Background:

• Beta-receptor antagonists (BB) improve outcomes in high-risk surgical patients.
• BB use is associated with better outcomes post-injury, but mechanisms are unclear.
• In vitro studies suggest BB modulate post-injury inflammatory responses.

Purpose of the Study:

• To investigate the effects of beta blockers (BB) on inflammatory profiles in injured patients at increased risk for heart disease.

Main Methods:

• A pseudo-randomized controlled trial involving injured patients over 55 admitted to the ICU.
• Patients received either continuous BB or standard care; observational arm for prehospital BB users.
• Plasma interleukin (IL)-6 and IL-1beta levels were measured at baseline and days 1, 2, and 4 post-BB initiation.

Main Results:

• Forty-two patients were enrolled; 17 in the control group and 25 receiving BB.
• No significant differences in demographics or baseline clinical characteristics between groups.
• IL-6 levels decreased over time in the BB group (p=0.04), while IL-1beta levels did not change significantly. Control group IL-6 levels remained unchanged (p=0.27).

Conclusions:

• Beta blocker (BB) use decreases serum IL-6 levels over time in injured, high-risk cardiac patients.
• This reduction in IL-6 may contribute to the improved outcomes observed in trauma patients treated with BB.
• BB administration in this patient population is safe once resuscitation endpoints are achieved.